Open Nav

OncoCyte Corporation

  • William Annett, OncoCyte Corporation

Inform investors about the Company's business and commercial potential.

  • Date:Thursday, October 18
  • Time:10:45 AM - 11:00 AM
  • Room:Elizabethan C
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Publicly Traded Company
  • Company Description/Mission Statement:OncoCyte is focused on the development and commercialization of novel, non-invasive blood and urine (“liquid biopsy”) diagnostic tests for the early detection of cancer. Early detection of cancer can improve health outcomes, reduce the cost of care, and improve patients’ quality of life. Liquid biopsy diagnostic tests like those OncoCyte is developing may reduce the need for costlier and riskier diagnostic procedures such as invasive biopsy and cystoscopic procedures. OncoCyte’s development pipeline is focused on non-invasive confirmatory diagnostic tests for lung, breast, and bladder cancer. OncoCyte’s tests are being developed using proprietary sets of genetic and protein molecular markers that differentially express in specific types of cancer. OncoCyte conducts ongoing research to identify additional molecular markers, acquire or license markers and related technology, and develop tests based on those markers.
  • Company
  • Company HQ City:Alameda
  • Company HQ Country:United States
  • Company HQ State:California                  
  • Market Cap:$124,000,000
  • Ticker:OCX
  • Exchange:NYSE American
  • CEO/Top Company Official:William Annett
  • Year Founded:2009
  • Main Therapeutic Focus:Diagnostics
  • Lead Product in Development :DetermaVu
  • Development Phase of Primary Product:Other/Not Applicable
William Annett
OncoCyte Corporation